healthtech.com/SBD

Register by March 9th

Save up to$350!

Co-Located with: Next-Gen Kinase Inhibitors:

Looking at the Path AheadJune 4-6, 2012

healthtech.com/KIN

Dinner Short Courses: First Principles in Binding Kinetics:

Towards Predicting Structure-Kinetics RelationshipsJune 6, 2012

PubChem Mining - From Small Molecule to Structures and Bioactivity June 7, 2012

Keynote Address Binding Kinetics in Drug Discovery

David Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)

Structure-BasedDRug DESIgN Predicting Biological

and Kinetic Profiles from Structure

June 6-8, 2012 • Royal Sonesta Hotel Boston • Cambridge, MA

Cambridge Healthtech Institute and Bio-IT World Present the Twelfth Annual

Organized by: Cambridge Healthtech Institute

Lead Media Partner:

Sponsoring Society:

Final Agenda

Corporate Sponsors:

2 | Structure-Based Drug Design healthtech.com/SBD

Wednesday, June 6

STRUCTURE TO FUNCTION11:45 AM Conference Registration

1:15 PM Chairperson’s RemarksChris Williams, Ph.D., Principal Scientist, Chemical Computing Group

1:20 Integrate Structural, Biophysical and Computational Methods to Understand Glucokinase Function and Design

Novel Allosteric ActivatorsXiayang Qiu, Ph.D., Senior Director, Head of Structure Biology & Biophysics, Pfizer, Inc. Despite the rapid advances in protein crystallography over the last two decades, SBDD successes still rely mostly on

the intuitions of our scientists due to the lack of reliable computational tools to predict affinity, kinetics, thermodynamics, solvation and conformational dynamics.  Through glucokinase and other examples, I will present our progresses in integrating diverse biophysical methods to strengthen the link between structure and function, and advocate for the development of predictive computational algorithms through expanded experimental datasets.

1:50 Structure-Guided Design of Biologically Active and Highly Selective Inhibitors of the CK1 Family of Protein Kinases for the Treatment of Cancer, Inflammation and Neurological DisordersScot Mente, Ph.D., Senior Research Scientist, Neuroscience Chemistry, PfizerStructure-guided design of biologically active and highly selective inhibitors of the CK1 family of protein kinases for the treatment of cancer, inflammation and neurological disorders. The CK1 family of protein kinases, previously known as the casein kinases, consists of seven moderately conserved isoforms in humans. This talk will review recent data which suggests that several CK1 isoforms may be attractive targets for pharmaceutical intervention in cancer, inflammation and neurological disorders.

2:20 Rational Approaches to Improving Sponsored by Selectivity in Drug DesignWoody Sherman, Ph.D., Vice President, Applications Science, Schrodinger, Inc.Optimizing binding selectivity is a key part of drug discovery. We present a survey of rational, structure-based approaches to selectivity design. We highlight the difference between broad and narrow selectivity and provide examples of how selectivity can be achieved using different molecular mechanisms.

2:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:30 Identification of DYG-out Inhibitors of LRRK2 Based on Structural Modeling and Enzyme Kinetic StudiesMin Liu, Ph.D., Assistant Director, The Laboratory of Drug Discovery for Neurodegeneration, LDDN, Harvard NeuroDiscovery Center, HNDC, Brigham and Women’s HospitalLeucine-rich repeat kinase2 (LRRK2), a large and complex protein that possesses two enzymatic properties, kinase and GTPase, is one of the major genetic factors in Parkinson’s disease (PD). Over 40 mutations in LRRK2 have been found in the most common familial forms and some sporadic forms of PD, and have been associated with typical idiopathic, late-onset PD. Here we report the identification of DYG-out inhibitors of LRRK2 based on the combined structural modeling and enzyme kinetic studies.

4:00 Determining the Crystal Structures of Allosteric Kinase Inhibitor Complexes            Barbara Brandhuber, Ph.D., Director, Early Drug Discovery, Biology, Array BioPharmaUpon discovery of a kinase inhibitor that does not appear to bind in the ATP-binding cleft, structural biologists are challenged to determine the crystal structure of the inhibitor-bound kinase to enable structure-based drug design. Frequently, the inhibitor does not crystallize with a canonical kinase construct and therefore a new crystallographic effort is launched. In this presentation,

several biochemical, biophysical, and bioinformatic approaches will be discussed which enable and complement crystallographic studies. The use of multi-disciplinary approaches to crystallographically determine the unique binding mode of an allosteric inhibitor interacting with both the regulatory pleckstrin-homology and kinase domains of AKT-1 will be described.

4:30 In silico Lead Finding through Holistic Understanding of Screening Data from Multiple ApproachesMeir Glick, Ph.D., Head, Lead Discovery Informatics, Novartis Institutes for BioMedical Research, Inc.Understanding of biochemical, biophysical, pathway and functional information is critical for decision making and hypothesis generation in drug discovery. We will discuss the in silico approaches to support this challenge. For example, design of bio-diverse compound libraries and intentional targeting of a specific phenotype. Next, we will describe how the data should be mined and visualized to enable understanding of the molecular mechanism of action and prioritize the right chemical matter for a chemistry program.

5:00 End of Day

6:00-8:00 pm DINNER SHORT COURSE*First Principles in Binding Kinetics: Towards Predicting Structure-Kinetics Relationships Instructors:David Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)Xavier Barril, Ph.D., ICREA Research Professor, Physical Chemistry Department, University of BarcelonaThis course will address the questions on “why should I care about kinetics?” and “how can I understand and predict Structure-Kinetics relationships?” We will first review the role of binding kinetics in drug action and then focus on the particular case of protein-ligand non-covalent complexes, reviewing what is known so far about the structural determinants of binding kinetics. This course will help you with a better understanding and increased awareness of current state of the chemistry and pharmacology of binding kinetics.

*Separate Registration Required

Thursday, June 7

FREE ENERGY CALCULATION AND MOLECULAR DYNAMICS SIMULATION

7:30 AM Morning Coffee

8:00 Chairperson’s RemarksWoody Sherman, Ph.D., Vice President, Applications Science, Schrodinger, Inc.

8:10 Free Energy Driven Geometrical Simulation of Protein Dynamics

Donald Jacobs, Ph.D., Associate Professor, Physics and Optical Science, UNC CharlotteGraph-rigidity plays an important role in (i) quantifying protein flexibility, (ii) exploring conformational dynamics using geometrical simulation (GS) and (iii) calculating free energy using a Distance Constraint Model (DCM). While GS explores

accessible geometries for a fixed constraint topology, the DCM generates an ensemble of constraint topologies for fixed geometry. Combining GS with the DCM yields a novel Monte Carlo method to efficiently explore conformational states along the free energy landscape of a protein, and this exploration can be directed.

8:40 Toward Antibody Drug Development Assisted by Molecular Dynamics Simulations

Takefumi Yamashita, Ph.D., Project Associate Professor, Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of TokyoIn order to develop an antibody drug, achieving high affinity through mutation is one of the most essential steps. I have

healthtech.com/SBD Structure-Based Drug Design | 3

been working on mutant antibodies specific for Roundabout homolog 1 (ROBO1), which is known as a hepatocellular carcinoma antigen, by utilizing molecular dynamics simulation techniques including a newly developed method to evaluate the absolute binding free energy. In my talk, I will discuss several key features of the single mutation of the antibody. In collaboration with experimentalists, we found that even the single mutation can affect the interface structure globally.

9:10 Making Docking/Scoring Calculations More Accurate via Error Analysis

Kenneth Merz, Jr., Ph.D., Professor of Chemistry, Quantum Theory Project, University of Florida GainesvilleDocking calculations are a mainstay of structure-based drug design and this talk addresses the central question regarding how potential function errors affect the (un)successful outcome of a docking effort. We analyze and estimate the magnitude

of potential function error and demonstrate how to use this knowledge to improve the outcome of a docking exercise.

9:40 Rationalization and Visualization Sponsored by of Nonbonded InteractionsChris Williams, Ph.D., Principal Scientist, Chemical Computing GroupThe visualization and assessment of the quality of non-bonded interactions in molecular modeling application is an important tool in structure-based drug desgin. Often, purely geo-metric criteria are used to score non-bonded interactions (such as hydrogen bonds). Such methods poorly represent the underlying chemistry of the interacting species. In this work, we present techniques based on Extended Hueckel Theory for scoring hydrogen bonds and make some generalizations for halogen bonds and sulfur-oxygen interactions.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:40 Exploring the S1P1 Ligand Binding Pocket through Structural AnalysisMichael Hanson, Ph.D., Associate Director, Structural Biology, Receptos, Inc.A structural view at 2.8 Å resolution of a lipid mediated GPCR reveals an access channel adjacent to the plasma membrane and provides supporting evidence for a volume triggered activation mechanism.  This structure, along with mutagenesis, agonist structure-activity relationship data and modeling, provides a detailed view of the molecular recognition and hydrophobic volume triggering that activates S1P1 resulting in the modulation of immune and stromal cell responses, which are therapeutically important for human diseases ranging from multiple sclerosis to influenza.

11:10 Binding Affinity Prediction for Drugs and Receptors Forming Multiple Species by Ionization and TautomerismStefan Balaz, Albany College of Pharmacy and Health Sciences, Vermont CampusTreatment of ionization and tautomerism of ligands and receptors is one of the unresolved issues in structure-based prediction of binding affinities. Our solution utilizes the thermodynamic master equation, expressing the experimentally observed association constant as the sum of products, each valid for a specific ligand-receptor species pair, consisting of the association microconstant and the fractions of the involved ligand and receptor species. The microconstants are characterized by structure-based simulations, which are run for individual species pairs. The concept will be illustrated for ligand-based CoMFA approach and receptor-based QM/MM linear response approach.

11:40 Pose Prediction with Confidence - Ligand Sponsored by and Structure based Flexible DockingBrian Kelley, OpenEye Scientific SoftwareTraditional structure based pose-prediction has not been very accurate in reproducing crystallographic poses. This can be rectified by using all of the information present in a crystal structure - both ligand and protein structure. POSIT is a flexible docking technique that uses both the known protein and ligand structure to predict poses. Furthermore, using this information generates a probability that the predicted pose is indeed correct. This has far reaching implications for real world lead optimization scenarios including measuring confidence but also the ability to select the existing crystal structure that best predicts the docked pose for a given molecule.

12:10 PM Luncheon Presentation (Opportunity Available) or Lunch on Your Own

FRAGMENT-BASED DESIGN1:30 Chairperson’s RemarksChristopher W. Murray, Ph.D., Vice President of Discovery Technology, Astex Pharmaceuticals

1:40 The Use of Fragment-Based Drug Discovery to Exploit Alternative Binding Sites on Proteins

Christopher W. Murray, Ph.D., Vice President of Discovery Technology, Astex PharmaceuticalsFragment-based drug discovery (FBDD) allows for the collection of large numbers of crystal structures co-soaked with fragments. We will describe a computational approach that searches the protein surface to detect binding at alternative sites away

from the known binding sites of the protein. Several examples will be given including the application of FBDD to the discovery of molecules that bind to a novel allosteric site on the full length NS3 protein from the Hepatitis C Virus.

2:10 Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment Based Drug DiscoverySandor Vajda, Ph.D., Professor, Biomedical Engineering and Chemistry, Boston UniversityProtein mapping, a computational method developed to find binding hot spots and implemented as the FTMap server, provides information that complements fragment screening results and can drive the evolution of core fragments into larger leads with a minimal loss or, in some cases, even a gain in ligand efficiency. We consider a variety of drug targets and show that the main hot spot identified by FTMap binds the core compound found by fragment screening. The most useful information is provided by the neighboring secondary hot spots, indicating the regions where the core can be extended to increase its affinity. To quantify this information, we calculate the density of probes from mapping, which describes the binding propensity at each point, and show that the change in the correlation between a ligand position and the probe density upon extending or repositioning the core moiety predicts the expected change in ligand efficiency.

2:40 A Fast Computational Method for Fragment Sponsored by Growing and Joining Using Molecular FieldsRae Lawrence, Technical Sales Manager, Cresset BioMolecular Discovery LtdThe use of fragments in medicinal chemistry is a powerful alternative technique for drug discovery. Our field based modelling approach provides fine detail irrespective of the size of molecule. We describe the use of sparkV10 in a rapid virtual fragment growth and joining exercise to facilitate the design of potential novel and selective P38 kinase inhibitors.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing

3:40 Decisions in Fragment Progression – Can Thermodynamics or Kinetics Help?Rod Hubbard, Ph.D., Director, Structural Sciences, Vernalis Ltd.

4:10 Drug Design and Repositioning Using Multiple Fragment Simultaneous Docking

Chenglong Li, Ph.D., Associate Professor, Medicinal Chemistry, The Ohio State UniversityWe use multiple fragment simultaneous docking to find the optimal fragment combinations binding to the most important target “hot spots,” followed by tethering to generate virtual template compounds. The fragments can be linked to generate

novel leads, and we designed two novel lead inhibitors based on one of the lead templates. Existing drugs can be repositioned for the new targets via the new lead templates. Case studies will be presented.

4:40 High-Throughput Synchrotron Crystallography for Fragment-Based, Structure-Guided Drug DiscoveryStephen R. Wasserman, Ph.D., Director, LRL Collaborative Access Team; Senior Research Fellow, Translational Science & Technologies, Eli Lilly and Company Advanced Photon Source Argonne National Laboratory

5:10-6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

4 | Structure-Based Drug Design healthtech.com/SBD

 6:30-8:30 DINNER SHORT COURSE*PubChem Mining - From Small Molecule to Structures and Bioactivity *Instructor:Jun (Luke) Huan, Ph.D., Associate Professor, Electrical Engineering and Computer Science Department, University of KansasIn this short course, the presenter will review the knowledge discovery and management needs in the drug discovery process. One part of the talk will focus on an introduction to PubChem, a public repository for small molecule structures and bioactivity data, where several components facilitating data mining of biological assays test results, including data organization, search of chemicals and analysis for assay development will be covered. On the second part, latest computing and modeling methodology development, primarily those from data mining and machine learning will be overviewed.

*Separate Registration Required

Friday, June 8

DRUGGABILITY AND KINETICS-BASED DRUG DESIGN

8:00 AM Chairperson’s RemarksRobert A. Copeland, Ph.D., Executive Vice President of R&D and Chief Scientific Officer, EpiZyme, Inc.”

8:10 Computational Target Evaluation and Lead Generation Strategies

Diane Joseph-McCarthy, Associate Director, Infection Computational Sciences, AstraZeneca Pharmaceuticals, Inc.Computational strategies for target evaluation and lead generation will be presented. Various computational approaches for assessment of binding site druggability, in particular with a view toward designing broad spectrum

antibacterials, will be described. In addition, the expanding role of virtual and fragment-based screening for lead generation in the drug discovery process will be discussed. Specifically, the combined use of computational and biophysical-based methods, the development of screening libraries, and the challenges overall will be highlighted.

8:40 Drug-Target Residence Time: An Alternative Approach to Lead Optimization

Robert A. Copeland, Ph.D., Executive Vice President of R&D and Chief Scientific Officer, EpiZyme, Inc.Durable pharmacologic activity depends not merely on the affinity of drug-target interactions but also on the lifetime of the drug-target complex in vivo. Residence time provides an experimental measure that related directly to the lifetime of

the drug-target complex. The residence time concept will be introduced and examples of its application for improving lead efficacy and safety will be presented. Structural features that facilitate long drug-target residence time will be discussed in the context of a new theoretical framework for drug dissociation: the retrograde induced-fit model.

9:10 Kinetically Informed and Structure-Based Drug DesignRumin Zhang, Ph.D., Biophysics Team Lead, In Vitro Pharmacology, Merck Research Laboratories

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

healthtech.com/SBD Structure-Based Drug Design | 5

»10:20 KeynoTe PresenTaTionBinding Kinetics in Drug Discovery

David Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)Binding kinetics are the rate of association (kon) and dissociation (koff) of a drug to a physiological target and are integral to a medicine’s efficacy, safety and selectivity. Greater understanding and application of

binding kinetics will to add value to drug discovery. Opportunities where value may be added include experimental design, molecular descriptors for chemical optimization, molecular mechanisms of action that increase efficacy, safety and the therapeutic index, duration of action and differentiation of medicines.

10:50 Water-Shielded Hydrogen Bonds: A Handle on Binding Kinetics of Protein-Ligand Complexes

Xavier Barril, Ph.D., ICREA Research Professor, Physical Chemistry Department, University of BarcelonaWith growing awareness about the fundamental role of binding kinetics for drug efficacy, there is a pressing need to understand and predict structure-kinetic relationships. We have recently shown that water-shielded hydrogen bonds act as kinetic traps, a knowledge

that creates opportunities to modulate the kinetic behavior of drug candidates (Schmidtke et al., JACS 2011; 133(46):18903). An overview of the principle will be presented along with our more recent research in the field.

11:20 Ligand-Target Residence Time Based Sponsored by Drug DiscoveryNils Hansen, Ph.D., CEO, Vipergen ApSThe lifetime of the drug-target complex quantified by its residence time is recognized as an important predictor of in vivo efficacy but is difficult to address in early drug

discovery efforts at desired throughputs. Binder Trap Enrichment® is a novel concept for identifying small molecules based on residence time from DNA-encoded chemical libraries. Here binding complexes of a DNA-encoded ligand and DNA-tagged target protein are trapped within emulsion droplets, thus allowing instant ligand ranking by residence time.

11:50 Luncheon Presentation (Opportunity Available) or Lunch on Your Own

TRENDS AND ADVANCES1:25 PM Chairperson’s RemarksFlorian Nigsch, Ph.D., Investigator I, Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research

1:30 Human Pocketome for Predicting Activities and Adverse Reactions

Ruben Abagyan, Ph.D., Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences, San Diego Supercomputer Center, University of California, San Diego Ligand docking and scoring to multiple conformations of the binding pocket of a target is a powerful and chemically unbiased predictor of compound activity. We developed a comprehensive set

of experimentally validated pockets in human proteome. Further, we optimized protocols of conformational selection, docking, scoring to those pockets or related ligand fields. The method can be used for screening, predicting subtype specificity, adverse effects and can guide a medicinal chemistry program.

2:00 Some Novel Methodologies that Complement Structure-Based ApproachesKiyoyuki Omoto, Ph.D., Computational Scientist, WorldWide Medicinal Chemistry, Pfizer NeusentisWhile some successful applications of structure-based drug design (SBDD)

healthtech.com/SBD Structure-Based Drug Design | 6

Web Partners:Lead Sponsoring Publications:

Sponsoring Publications: Web Partner:

EXHIBIT & SPONSORSHIP OPPORTUNITIES

Structure-Based Drug Design presents your company with the opportunity to network with decision-makers and leading professionals from throughout the biopharmaceutical community. By participating as a Sponsor and Exhibitor, your company can identify new business leads, market new technology and increase brand awareness, while positioning itself as a thought-leader amongst qualified buyers.

OPPORTUNITIES INCLUDE:

Sponsored Presentations

Showcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding and access to cooperative marketing efforts by Cambridge Healthtech Institute (CHI).

Breakfast & Luncheon Presentations

Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite

Sponsors will hand-pick their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives (i.e. purely social, focus group, reception style or plated dinner, plated dinner with specific conversation focus).

CHI Lead Generation

CHI can help you with lead generation throughout the year. Our internal database includes over 800,000 prospects in the life sciences. By leveraging the database and mining for your specific requirements, we can produce multiple custom projects which will deliver your prospective buyers: Web Symposiums, Podcasts, White Papers, Custom Market Research Surveys and more!

Exhibit Information

Exhibitors will enjoy facilitated networking opportunities with qualified decision makers at Structure-Based Drug Design, making it the perfect platform to launch a new product, collect feedback and generate new leads. Exhibit space sells out quickly, so reserve yours today!

To find out more about our comprehensive sponsorship and exhibit packages, please contact:

Jon Stroup

Manager, Business Development

781-972-5483

jstroup@healthtech.com

HOTEL & TRAVEL INFORMATION

Conference Venue and Hotel:

Royal Sonesta Hotel Boston

40 Edwin H. Land Boulevard

Cambridge, MA 02142

Phone: 617-806-4200

Discounted Room Rate: $249 s/d

Discounted Room Rate Cut-off Date: May 8, 2012

Please visit our conference website to make your reservations or call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:

Special discount rentals have been established with American Airlines for this conference. • Call American Airlines 1-800-433-1790 use Conference code 7162AX.• Go to www.aa.com/group enter Conference code 7162AX in promotion

discount box.• Contact our dedicated travel agents at 1-877-559-5549 or

chi@protravelinc.com.

Car Rental Discounts:

Special discount rentals have been established with Hertz for this conference.• Call Hertz 1-800-654-3131 use our Hertz Convention Number (CV):

04KL0003• Go to www.hertz.com use our Hertz Convention Number

(CV): 04KL0003

CO-LOCATED WITH

Cambridge Healthtech Institute’s Tenth Annual

Next-Gen Kinase Inhibitors: The Path AheadJune 4-6, 2012

Best Value! Register for the Structure-Based Drug Design and Kinase conferences at a special rate.

healthtech.com/KIN

If you are unable to attend but would like to purchase the Structure-Based Drug Design CD for $350 (plus shipping), please visit healthtech.com/SBD. Massachusetts delivery will include sales tax.

Receive a FREE eNewsletter by signing up at chimediagroup.com

The latest industry news, commentary and highlights from Bio-IT World

Innovative management in clinical trials

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets.For a detailed list of reports, visit InsightPharmaReports.com, or contact Rose LaRaia, rlaraia@healthtech.com, +1-781-972-5444.

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit barnettinternational.com.

AddItIonAl regIstrAtIon detAIlsEach registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

to view our substitutions/Cancellations Policy, go to http://www.healthtech.com/regdetails

Video and or audio recording of any kind is prohibited onsite at all CHI events.

Cambridge Healthtech Institute250 First Avenue, Suite 300Needham, MA 02494www.healthtech.comFax: 781-972-5425

Pricing and registration InformationstruCture-bAsed drug desIgn (june 6-8, 2012)

Academic, Government, Commercial Hospital-affiliated

Early Registration Discount until March 9, 2012 $1695 $820Advance Registration Discount until April 27, 2012 $1845 $900Registrations after April 27, 2012, and on-site $2045 $970

struCture-bAsed drug desIgn & next-gen kInAse InHIbItors (june 4-8, 2012)

Early Registration Discount until March 9, 2012 $2640 $1320Advance Registration Discount until April 27, 2012 $2790 $1390Registrations after April 27, 2012, and on-site $2990 $1410

sHort Courses (june 6, 2012) Academic, Government, Commercial Hospital-affiliated

One Short Course $495 $245Two Short Courses $895 $445

ConferenCe dIsCounts

International society for Computational biology (IsCb) Member discount: 10% Off.Discount is subject to verification

Poster submission-Discount ($50 Off)Poster abstracts are due by May 9, 2012. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

regIster 3 - 4th Is free: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

How to Register: healthtech.com/SBDreg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode sbd f

when registering!

Structure-BasedDRug DESIgNJune 6-8, 2012 Royal Sonesta Hotel Boston, Cambridge, MA

Cambridge Healthtech Institute and Bio-IT World Present the Twelfth Annual